You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 23, 2024

CLINICAL TRIALS PROFILE FOR MOMELOTINIB DIHYDROCHLORIDE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for MOMELOTINIB DIHYDROCHLORIDE

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00935987 ↗ Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET) Completed Gilead Sciences Phase 1/Phase 2 2009-11-01 This study seeks to (i) determine a safe and tolerated dose of CYT387 (momelotinib) given to patients with PMF, post-PV or post-ET and, (ii) assess the effectiveness of orally-administered CYT387 as a treatment for PMF, post-PV or post-ET.
NCT00935987 ↗ Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET) Completed Sierra Oncology, Inc. Phase 1/Phase 2 2009-11-01 This study seeks to (i) determine a safe and tolerated dose of CYT387 (momelotinib) given to patients with PMF, post-PV or post-ET and, (ii) assess the effectiveness of orally-administered CYT387 as a treatment for PMF, post-PV or post-ET.
NCT01236638 ↗ Extension Study Evaluating the Long Term Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET) Completed Gilead Sciences Phase 2 2010-11-01 This extension protocol to the core study CCL09101 allows patients who have tolerated the drug and derived a clinical benefit, to continue to receive treatment beyond the 9 cycles of the core protocol. Long term safety and efficacy of CYT387 (momelotinib) will be evaluated.
NCT01236638 ↗ Extension Study Evaluating the Long Term Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET) Completed Sierra Oncology, Inc. Phase 2 2010-11-01 This extension protocol to the core study CCL09101 allows patients who have tolerated the drug and derived a clinical benefit, to continue to receive treatment beyond the 9 cycles of the core protocol. Long term safety and efficacy of CYT387 (momelotinib) will be evaluated.
NCT01423058 ↗ Safety Study Evaluating Twice-Daily Administration of Momelotinib in Primary Myelofibrosis or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis Completed Gilead Sciences Phase 1/Phase 2 2011-08-01 The myeloproliferative neoplasms (MPN), most notably polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) are a diverse but inter-related suite of clonal disorders of pluripotent hematopoietic stem cells (Tefferi et al., 2008). The MPN share a range of biological, pathological, and clinical features including the relative overproduction of one or more cells of myeloid origin, growth factor independent colony formation in vitro, marrow hypercellularity, extramedullary hematopoiesis, spleno- and hepatomegaly, and thrombotic and/or hemorrhagic diatheses (Tefferi et al., 2005). This is a multi-centre, open-label, non-randomized, dose-escalation study, to be conducted in two phases: a dose-escalation phase (Part 1), to determine the safety and tolerability of momelotinib (CYT387), and to identify a therapeutic dose for the expanded cohort; and a dose-confirmation phase (Part 2), which will be a cohort expansion at or below the MTD of momelotinib. In the Part I dose-escalation phase of the study, subjects will be assigned to dose levels in successive cohorts starting with a dose in the first cohort of 200 mg BID (twice daily with doses taken approximately 12 hours apart). Doses will be escalated by 50 mg BID per cohort until dose-limiting toxicities are observed. The dose level at which ≥2 of 6 subjects develop a first cycle dose-limiting toxicity (DLT) is defined as the DLT level. The maximum tolerated dose (MTD) is defined as the dose level below the DLT level. New dose levels may begin accrual only if all subjects at the current dose level have been observed for a minimum of 28 days from the first day of treatment. The dose level chosen for study in the dose confirmation phase of the study will be the MTD or a lower dose shown to have significant clinical activity (efficacy) as determined by the safety review committee. Subjects will be evaluated weekly for the first cycle, every 2 weeks during cycle 2, then monthly for 4 cycles for a total of 6 cycles. In the dose-confirmation phase of the study, approximately fifty (50) subjects will be treated at the MTD or at a lower dose shown to have significant clinical activity (efficacy) as chosen by the Safety Review Committee. In the dose confirmation phase of the study subjects will be evaluated every 2 weeks during the first treatment cycle, and then monthly for 5 cycles for a total of 6 cycles.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for MOMELOTINIB DIHYDROCHLORIDE

Condition Name

Condition Name for MOMELOTINIB DIHYDROCHLORIDE
Intervention Trials
Primary Myelofibrosis 8
Post-Essential Thrombocythemia Myelofibrosis 7
Post-polycythemia Vera Myelofibrosis 6
Primary Myelofibrosis (PMF) 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for MOMELOTINIB DIHYDROCHLORIDE
Intervention Trials
Primary Myelofibrosis 12
Polycythemia 11
Thrombocytosis 11
Thrombocythemia, Essential 11
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for MOMELOTINIB DIHYDROCHLORIDE

Trials by Country

Trials by Country for MOMELOTINIB DIHYDROCHLORIDE
Location Trials
United States 125
Canada 32
France 22
Australia 20
Poland 19
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for MOMELOTINIB DIHYDROCHLORIDE
Location Trials
California 15
Arizona 8
Massachusetts 8
Missouri 8
Texas 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for MOMELOTINIB DIHYDROCHLORIDE

Clinical Trial Phase

Clinical Trial Phase for MOMELOTINIB DIHYDROCHLORIDE
Clinical Trial Phase Trials
Phase 3 5
Phase 2 7
Phase 1/Phase 2 2
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for MOMELOTINIB DIHYDROCHLORIDE
Clinical Trial Phase Trials
Completed 7
Terminated 5
Recruiting 3
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for MOMELOTINIB DIHYDROCHLORIDE

Sponsor Name

Sponsor Name for MOMELOTINIB DIHYDROCHLORIDE
Sponsor Trials
Sierra Oncology, Inc. 14
Gilead Sciences 13
Incyte Corporation 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for MOMELOTINIB DIHYDROCHLORIDE
Sponsor Trials
Industry 32
NIH 2
Other 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.